Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

238,066 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Autologous T Cells Expressing CD30 Chimeric Antigen Receptors for Relapsed or Refractory Hodgkin Lymphoma: An Open-Label Phase I Trial.
Wang CM, Wu ZQ, Wang Y, Guo YL, Dai HR, Wang XH, Li X, Zhang YJ, Zhang WY, Chen MX, Zhang Y, Feng KC, Liu Y, Li SX, Yang QM, Han WD. Wang CM, et al. Among authors: zhang wy, zhang yj, zhang y. Clin Cancer Res. 2017 Mar 1;23(5):1156-1166. doi: 10.1158/1078-0432.CCR-16-1365. Epub 2016 Aug 31. Clin Cancer Res. 2017. PMID: 27582488 Clinical Trial.
Phase Ib/II study of safety and efficacy of low-dose decitabine-primed chemoimmunotherapy in patients with drug-resistant relapsed/refractory alimentary tract cancer.
Chen M, Nie J, Liu Y, Li X, Zhang Y, Brock MV, Feng K, Wu Z, Li X, Shi L, Li S, Guo M, Mei Q, Han W. Chen M, et al. Among authors: zhang y. Int J Cancer. 2018 Sep 15;143(6):1530-1540. doi: 10.1002/ijc.31531. Epub 2018 Apr 26. Int J Cancer. 2018. PMID: 29663379 Free PMC article. Clinical Trial.
Camrelizumab Plus Gemcitabine, Vinorelbine, and Pegylated Liposomal Doxorubicin in Relapsed/Refractory Primary Mediastinal B-Cell Lymphoma: A Single-Arm, Open-Label, Phase II Trial.
Mei Q, Zhang W, Liu Y, Yang Q, Rasko JEJ, Nie J, Liu J, Li X, Dong L, Chen M, Zhang Y, Shi L, Wu H, Han W. Mei Q, et al. Among authors: zhang w, zhang y. Clin Cancer Res. 2020 Sep 1;26(17):4521-4530. doi: 10.1158/1078-0432.CCR-20-0514. Epub 2020 Jun 4. Clin Cancer Res. 2020. PMID: 32499235 Clinical Trial.
Treatment of CD20-directed Chimeric Antigen Receptor-modified T cells in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an early phase IIa trial report.
Zhang WY, Wang Y, Guo YL, Dai HR, Yang QM, Zhang YJ, Zhang Y, Chen MX, Wang CM, Feng KC, Li SX, Liu Y, Shi FX, Luo C, Han WD. Zhang WY, et al. Among authors: zhang yj, zhang y. Signal Transduct Target Ther. 2016 Mar 11;1:16002. doi: 10.1038/sigtrans.2016.2. eCollection 2016. Signal Transduct Target Ther. 2016. PMID: 29263894 Free PMC article.
238,066 results
You have reached the last available page of results. Please see the User Guide for more information.